Next Level Private LLC Purchases 8,093 Shares of Bristol Myers Squibb Company $BMY

Next Level Private LLC boosted its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 12.4% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 73,247 shares of the biopharmaceutical company’s stock after purchasing an additional 8,093 shares during the quarter. Bristol Myers Squibb comprises about 0.8% of Next Level Private LLC’s holdings, making the stock its 27th biggest holding. Next Level Private LLC’s holdings in Bristol Myers Squibb were worth $4,220,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Allied Private Wealth LLC purchased a new position in Bristol Myers Squibb in the 2nd quarter worth approximately $138,000. Roan Capital Partners boosted its stake in Bristol Myers Squibb by 5.0% during the 2nd quarter. Roan Capital Partners now owns 4,589 shares of the biopharmaceutical company’s stock valued at $264,000 after purchasing an additional 218 shares during the last quarter. Valeo Financial Advisors LLC increased its holdings in shares of Bristol Myers Squibb by 2.6% in the 2nd quarter. Valeo Financial Advisors LLC now owns 29,784 shares of the biopharmaceutical company’s stock worth $1,716,000 after purchasing an additional 753 shares in the last quarter. MRA Advisory Group bought a new stake in shares of Bristol Myers Squibb in the 2nd quarter worth $1,363,000. Finally, Platt Investment Counsel LLC purchased a new position in shares of Bristol Myers Squibb in the second quarter worth $491,000. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb Stock Performance

Shares of NYSE BMY opened at $64.63 on Monday. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $68.10. The firm has a market capitalization of $132.02 billion, a price-to-earnings ratio of 14.24, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. The firm has a 50 day moving average of $58.71 and a 200 day moving average of $58.66.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.60 by $0.44. The business had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The company’s quarterly revenue was up 5.7% on a year-over-year basis. During the same period last year, the firm earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, research analysts anticipate that Bristol Myers Squibb Company will post 6.96 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 3.9%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 55.51%.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Analyst upgrades improve sentiment. Argus upgraded BMY to Buy, while Zacks raised the stock to a Rank #2 (Buy), citing improving earnings prospects. These recommendations may attract additional income- and value-oriented investors. Argus Upgrades Bristol Myers Squibb to Buy Bristol Myers Moves to Buy
• Positive Sentiment: Recent earnings exceeded expectations. Bristol Myers Squibb reported quarterly earnings of $2.04 per share versus the $1.60 consensus estimate, while revenue of $12.97 billion surpassed the $11.74 billion forecast. Revenue also grew 5.7% year over year, reinforcing the positive earnings narrative discussed on the company’s earnings call. Bristol Myers Squibb Q2 Earnings Call
• Positive Sentiment: Pipeline and research investments provide longer-term support. BMY is launching a real-world study examining luspatercept use in anemia care, while an expanded partnership with Schrödinger will deploy AI drug-discovery tools across BMS teams. These initiatives could improve evidence generation and help accelerate future medicines. Bristol Myers Squibb Tracks Luspatercept Use Schrödinger and BMS Expand Partnership
• Neutral Sentiment: Broader optimism around potential biotech and pharmaceutical catalysts may support sector sentiment, but the cited drug-development opportunities are not specific to BMY. New Drugs Could Fuel Pharma Stock Gains

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on BMY shares. Roth Capital began coverage on Bristol Myers Squibb in a research report on Wednesday. They set a “buy” rating and a $75.00 price objective on the stock. Sanford C. Bernstein raised Bristol Myers Squibb from a “market perform” rating to an “outperform” rating in a research report on Wednesday. Royal Bank Of Canada upped their target price on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “sector perform” rating in a research note on Friday, July 31st. Guggenheim reaffirmed a “buy” rating and set a $75.00 price target (up from $72.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. Finally, Weiss Ratings raised shares of Bristol Myers Squibb from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, July 30th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Bristol Myers Squibb currently has an average rating of “Moderate Buy” and an average target price of $66.06.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.